A pill that works the way Viagra does has slowed the progression of Alzheimer’s disease in one group of patients in a clinical study — but failed to reach statistical significance in the trial’s broader population, The Guardian and The Independent reported. Both halves of that sentence matter.
The drug, AR1001, is made by the South Korean company AriBio. It is a PDE-5 inhibitor — the same class of drug as Viagra — which relaxes blood vessels and increases blood flow. In a specific cohort of patients who were taking no other Alzheimer’s therapies, it reduced clinical deterioration by 31%. In the wider group, the effect did not clear the bar of statistical significance, which is the standard a drug must meet before anyone should treat the result as established.
Why researchers are interested anyway
Dr Richard Oakley of the Alzheimer’s Society described the approach as novel: relaxing blood vessels to increase blood flow to the brain. AR1001 is also an oral tablet — a practical advantage over the disease-modifying Alzheimer’s treatments that exist, which are given by injection or infusion.
The honest bottom line
Subgroup results in trials are where promising drugs most often mislead: slice a trial’s patients enough ways and one slice will usually show something. AR1001 is not available, has not been approved, and needs further assessment before anyone can say whether the 31% figure is a real effect or a statistical artefact. It is a lead worth following — reported here as exactly that, and nothing more.


0 comments